Results 111 to 120 of about 21,936 (207)

Platelet Drp1 phosphorylation provides a platform for immune-based platelet function testing. [PDF]

Blood
Barrios DA, Guo S, Powers M, Koseoglu S, Zerbey S, Lu R, Cermak A, Vayne C, Khan S, Aisiku O, Urman A, Thomas J, Patell R, Zwicker JI, Flaumenhaft R.   +14 more
europepmc   +1 more source

The efficacy and safety of ticagrelor and prasugrel versus clopidogrel in post-PCI dual antiplatelet therapy in chronic coronary syndrome: a systematic review and meta-analysis. [PDF]

BMC Cardiovasc Disord
Mirhosseini SA, Mousavi A, Dastjerdi P, Abdollahi M, Yazdanpanah H, Barahimi M, Mirzaei A, Moshfeghinia R, Ranjbar M, Azami P, Abdollahi A, Bakhshi H, Attar A.   +12 more
europepmc   +1 more source

2025 Acute Coronary Syndrome Guideline: Missing the Boat on <i>CYP2C19</i> Genotyping. [PDF]

J Am Heart Assoc
Cavallari LH, Lee CR, Beitelshees AL, Luzum JA, Stouffer GA, Ten Berg JM, van den Broek WWA, Pereira NL, Sibbing D, Angiolillo DJ.   +9 more
europepmc   +1 more source

Dual antiplatelet therapy in acute ischemic stroke: Does diabetes mellitus define a target population? [PDF]

Neurotherapeutics
Nedelcu S.
europepmc   +1 more source

P2Y12 Inhibitor–Based Monotherapy

Journal of the American College of Cardiology, 2020
Rahul Choudhary, Surender Deora
openaire   +1 more source

The performance of ASpirin-FREE therapy after successful percutaneous coronary intervention for acute coronary syndrome: the ASFREE prospective pilot study. [PDF]

J Yeungnam Med Sci
Joo D, Jo S, Byoun JT, Cho JY, Yun KH.
europepmc   +1 more source

In Hospital Assessment and Management of High Bleeding Risk in Patients with ST-Elevation Myocardial Infarction (STEMI). [PDF]

J Cardiovasc Dev Dis
Kim S, Piserra-López A, Giordano S, Laudani C, Costa F, González-Aguado N, Corcione N, Angiolillo DJ, Ortega-Paz L.   +8 more
europepmc   +1 more source

Personalized P2Y12 Inhibitor Treatment

JACC: Cardiovascular Interventions, 2020
Jurriën M. ten Berg, Paul W.A. Janssen
openaire   +1 more source

Single-Site Experience in the ONSET-OFFSET Study Demonstrates Pharmacodynamic and Pharmacokinetic Advantages of Ticagrelor over Clopidogrel in Patients with Chronic Coronary Syndromes. [PDF]

J Cardiovasc Dev Dis
Judge HM, Parker WAE, Storey RF.
europepmc   +1 more source

Redefining Dual Antiplatelet Strategies After Acute Coronary Syndrome: Insights from Recent RCTs. [PDF]

J Clin Med
He M, Magdy J, Aziz M, Tan J, Das A, Wheatcroft SB, Bulluck H.   +6 more
europepmc   +1 more source